Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Direct-acting antivirals
Hepatitis C Virus
rare HCV genotypes
resistance-associated substitutions
treatment response
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
29
12
2023
revised:
15
03
2024
accepted:
18
03
2024
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
epublish
Résumé
Data on the prevalence and characteristics of so-called rare HCV genotypes (GTs) in larger cohorts is limited. This study investigates the frequency of rare GT and resistance-associated substitutions and the efficacy of retreatment in a European cohort. A total of 129 patients with rare GT1-6 were included from the European resistance database. NS3, NS5A, and NS5B were sequenced and clinical parameters and retreatment efficacies were collected retrospectively. Overall 1.5% (69/4,656) of direct-acting antiviral (DAA)-naive and 4.4% (60/1,376) of DAA-failure patients were infected with rare GT. Although rare GTs were almost equally distributed throughout GT1-6 in DAA-naive patients, we detected mainly rare GT4 (47%, 28/60 GT4; of these n = 17, subtype 4r) and GT3 (25%, 15/60 GT3, of these n = 8, subtype 3b) among DAA-failures. A total of 62% (37/60) of DAA failures had not responded to first-generation regimes and the majority was infected with rare GT4 (57%, 21/37). In contrast, among patients with failure to pangenotypic DAA regimens (38%, 23/60), infections with rare GT3 were overrepresented (57%, 13/23). Although NS5A RASs were uncommon in rare GT2, GT5a, and GT6, we observed combined RASs in rare GT1, GT3, and GT4 at positions 28, 30, 31, which can be considered as inherent. DAA failures with completed follow-up of retreatment, achieved a high SVR rate (94%, 45/48 modified intention-to-treat analysis; 92%, 45/49 intention-to-treat). Three patients with GT4f, 4r, or 3b, respectively, had virological treatment failure. In this European cohort, rare HCV GT were uncommon. Accumulation of specific rare GT in DAA-failure patients suggests reduced antiviral activities of DAA regimens. The limited global availability of pangenotypic regimens for first line therapy as well as multiple targeted regimens for retreatment could result in HCV elimination targets being delayed. Data on the prevalence and characteristics of rare HCV genotypes (GT) in larger cohorts are still scarce. This study found low rates of rare HCV GTs among European HCV-infected patients. In direct-acting antiviral (DAA)-failure patients, rare GT3 subtypes accumulated after pangenotypic DAA treatment and rare GT4 after first generation DAA failure and viral resistance was detected at NS5A positions 28, 30, and 31. The limited global availability of pangenotypic DAA regimens for first line therapy as well as multiple targeted regimens for retreatment could result in HCV elimination targets being delayed.
Sections du résumé
Background and Aims
UNASSIGNED
Data on the prevalence and characteristics of so-called rare HCV genotypes (GTs) in larger cohorts is limited. This study investigates the frequency of rare GT and resistance-associated substitutions and the efficacy of retreatment in a European cohort.
Methods
UNASSIGNED
A total of 129 patients with rare GT1-6 were included from the European resistance database. NS3, NS5A, and NS5B were sequenced and clinical parameters and retreatment efficacies were collected retrospectively.
Results
UNASSIGNED
Overall 1.5% (69/4,656) of direct-acting antiviral (DAA)-naive and 4.4% (60/1,376) of DAA-failure patients were infected with rare GT. Although rare GTs were almost equally distributed throughout GT1-6 in DAA-naive patients, we detected mainly rare GT4 (47%, 28/60 GT4; of these n = 17, subtype 4r) and GT3 (25%, 15/60 GT3, of these n = 8, subtype 3b) among DAA-failures. A total of 62% (37/60) of DAA failures had not responded to first-generation regimes and the majority was infected with rare GT4 (57%, 21/37). In contrast, among patients with failure to pangenotypic DAA regimens (38%, 23/60), infections with rare GT3 were overrepresented (57%, 13/23). Although NS5A RASs were uncommon in rare GT2, GT5a, and GT6, we observed combined RASs in rare GT1, GT3, and GT4 at positions 28, 30, 31, which can be considered as inherent. DAA failures with completed follow-up of retreatment, achieved a high SVR rate (94%, 45/48 modified intention-to-treat analysis; 92%, 45/49 intention-to-treat). Three patients with GT4f, 4r, or 3b, respectively, had virological treatment failure.
Conclusions
UNASSIGNED
In this European cohort, rare HCV GT were uncommon. Accumulation of specific rare GT in DAA-failure patients suggests reduced antiviral activities of DAA regimens. The limited global availability of pangenotypic regimens for first line therapy as well as multiple targeted regimens for retreatment could result in HCV elimination targets being delayed.
Impact and implications
UNASSIGNED
Data on the prevalence and characteristics of rare HCV genotypes (GT) in larger cohorts are still scarce. This study found low rates of rare HCV GTs among European HCV-infected patients. In direct-acting antiviral (DAA)-failure patients, rare GT3 subtypes accumulated after pangenotypic DAA treatment and rare GT4 after first generation DAA failure and viral resistance was detected at NS5A positions 28, 30, and 31. The limited global availability of pangenotypic DAA regimens for first line therapy as well as multiple targeted regimens for retreatment could result in HCV elimination targets being delayed.
Identifiants
pubmed: 39006503
doi: 10.1016/j.jhepr.2024.101072
pii: S2589-5559(24)00076-4
pmc: PMC11246049
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101072Investigateurs
C Antoni
(C)
A Teufel
(A)
R Vogelmann
(R)
M Ebert
(M)
J Balavoine
(J)
E Giostra
(E)
M Berning
(M)
J Hampe
(J)
T Boettler
(T)
C Neumann-Haefelin
(C)
R Thimme
(R)
A De Gottardi
(A)
A Rauch
(A)
N Semmo
(N)
V Ellenrieder
(V)
M Gress
(M)
A Herrmann
(A)
A Stallmach
(A)
D Hoffmann
(D)
U Protzer
(U)
A Kodal
(A)
M Löbermann
(M)
T Götze
(T)
V Keitel-Anselmino
(V)
C M Lange
(CM)
R Zachoval
(R)
J Mayerle
(J)
A Maieron
(A)
P Michl
(P)
U Merle
(U)
D Moradpour
(D)
J-P Chave
(JP)
M Muche
(M)
H-J Epple
(HJ)
M Müller-Schilling
(M)
F Kocheise
(F)
T Müller
(T)
F Tacke
(F)
E Roeb
(E)
J Rissland
(J)
M Krawczyk
(M)
P Schulze
(P)
D Semela
(D)
U Spengler
(U)
J Rockstroh
(J)
C P Strassburg
(CP)
J Siebler
(J)
J Schulze Zur Wiesch
(J)
F Piecha
(F)
J von Felden
(J)
S Jordan
(S)
A Lohse
(A)
M Sprinzl
(M)
P Galle
(P)
R Stauber
(R)
B Strey
(B)
W Steckstor
(W)
W Schmiegel
(W)
N H Brockmeyer
(NH)
A Canbay
(A)
C Trautwein
(C)
F Uschner
(F)
J Trebicka
(J)
T Weber
(T)
H Wedemeyer
(H)
M Cornberg
(M)
M Manns
(M)
P Wietzke-Braun
(P)
R Günther
(R)
K Willuweit
(K)
G Hilgard
(G)
H Schmidt
(H)
E Zizer
(E)
J Backhus
(J)
T Seufferlein
(T)
O Al-Taie
(O)
W Angeli
(W)
S Beckebaum
(S)
A Erhardt
(A)
A Garrido-Lüneburg
(A)
H Gattringer
(H)
D Genné
(D)
M Gschwantler
(M)
F Gundling
(F)
S Hametner
(S)
R Schöfl
(R)
S Haag
(S)
H Heinzow
(H)
T Heyer
(T)
C Hirschi
(C)
A Jussios
(A)
S Kanzler
(S)
N Kordecki
(N)
M Kraus
(M)
U Kullig
(U)
S Wollschläger
(S)
L Magenta
(L)
B Terziroli Beretta-Piccoli
(BT)
M Menges
(M)
L Mohr
(L)
K Muehlenberg
(K)
C Niederau
(C)
B Paulweber
(B)
A Petrides
(A)
M Pinkernell
(M)
R Piso
(R)
W Rambach
(W)
L Reinhardt
(L)
M Reiser
(M)
B Riecken
(B)
A Rieke
(A)
J Roth
(J)
M Schelling
(M)
P Schlee
(P)
A Schneider
(A)
D Scholz
(D)
E Schott
(E)
M Schuchmann
(M)
U Schulten-Baumer
(U)
A Seelhoff
(A)
A Stich
(A)
F Stickel
(F)
J Ungemach
(J)
E Walter
(E)
A Weber
(A)
H Wege
(H)
T Winzer
(T)
W Abels
(W)
M Adler
(M)
F Audebert
(F)
C Baermann
(C)
E Bästlein
(E)
R Barth
(R)
K Barthel
(K)
W Becker
(W)
J Behrends
(J)
J Benninger
(J)
F Berger
(F)
D Berzow
(D)
T Beyer
(T)
M Bierbaum
(M)
O Blaukat
(O)
A Bodtländer
(A)
G Böhm
(G)
N Börner
(N)
U Bohr
(U)
B Bokemeyer
(B)
H R Bruch
(HR)
D Bucholz
(D)
P Buggisch
(P)
K Matschenz
(K)
J Petersen
(J)
O Burkhard
(O)
N Busch
(N)
C Chirca
(C)
R Delker
(R)
J Diedrich
(J)
M Frank
(M)
M Diehl
(M)
A O Tal
(AO)
M Schneider
(M)
A Dienethal
(A)
P Dietel
(P)
N Dikopoulos
(N)
M Dreck
(M)
F Dreher
(F)
L Drude
(L)
K Ende
(K)
U Ehrle
(U)
K Baumgartl
(K)
F Emke
(F)
R Glosemeyer
(R)
G Felten
(G)
D Hüppe
(D)
J Fischer
(J)
U Fischer
(U)
D Frederking
(D)
B Frick
(B)
G Friese
(G)
B Gantke
(B)
P Geyer
(P)
H R Schwind
(HR)
M Glas
(M)
T Glaunsinger
(T)
F Goebel
(F)
U Göbel
(U)
B Görlitz
(B)
R Graf
(R)
H Gruber
(H)
C Hartmann
(C)
C Klag
(C)
G Härter
(G)
M Herder
(M)
T Heuchel
(T)
S Heuer
(S)
H Hinrichsen
(H)
B Seegers
(B)
K-H Höffl
(KH)
H Hörster
(H)
J-U Sonne
(JU)
W P Hofmann
(WP)
F Holst
(F)
M Hunstiger
(M)
A Hurst
(A)
E Jägel-Guedes
(E)
C John
(C)
M Jung
(M)
B Kallinowski
(B)
B Kapzan
(B)
W Kerzel
(W)
P Khaykin
(P)
M Klarhof
(M)
U Klüppelberg
(U)
None Wolfratshausen
K Klugewitz
(K)
B Knapp
(B)
U Knevels
(U)
T Kochsiek
(T)
A Körfer
(A)
A Köster
(A)
M Kuhn
(M)
A Langekamp
(A)
B Künzig
(B)
R Link
(R)
M Littman
(M)
H Löhr
(H)
T Lutz
(T)
P Gute
(P)
G Knecht
(G)
U Lutz
(U)
D Mainz
(D)
I Mahle
(I)
P Maurer
(P)
S Mauss
(S)
C Mayer
(C)
H Möller
(H)
R Heyne
(R)
D Moritzen
(D)
M Mroß
(M)
M Mundlos
(M)
U Naumann
(U)
O Nehls
(O)
None K
R Ningel
(R)
A Oelmann
(A)
H Olejnik
(H)
K Gadow
(K)
E Pascher
(E)
A Philipp
(A)
M Pichler
(M)
F Polzien
(F)
R Raddant
(R)
M Riedel
(M)
S Rietzler
(S)
M Rössle
(M)
W Rufle
(W)
A Rump
(A)
C Schewe
(C)
C Hoffmann
(C)
D Schleehauf
(D)
W Schmidt
(W)
G Schmidt-Heinevetter
(G)
J Schmidtler-von Fabris
(JS)
L Schneider
(L)
A Schober
(A)
S Niehaus-Hahn
(S)
J Schwenzer
(J)
B Seegers
(B)
T Seidel
(T)
G Seitel
(G)
C Sick
(C)
K Simon
(K)
D Stähler
(D)
F Stenschke
(F)
H Steffens
(H)
K Stein
(K)
M Steinmüller
(M)
T Sternfeld
(T)
B Strey
(B)
K Svensson
(K)
W Tacke
(W)
G Teuber
(G)
K Teubner
(K)
J Thieringer
(J)
A Tomesch
(A)
U Trappe
(U)
J Ullrich
(J)
G Urban
(G)
S Usadel
(S)
A von Lucadou
(A)
F Weinberger
(F)
M Werheid-Dobers
(M)
P Werner
(P)
T Winter
(T)
E Zehnter
(E)
A Zipf
(A)
Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
JD: research support from Gilead. CG: speaking and/or consulting fees from AbbVie and travel support from AbbVie and Gilead. CPB: speaking and/or consulting fees: AbbVie, BMS, Gilead, Merck/MSD. KP: no conflicts to disclose. KD: speaking and/or consulting fees: Gilead, AbbVie, Alnylam. PB: speaking and/or consulting fees: AbbVie, BMS, Falk, Gilead, Janssen, Merz Pharma, Merck/MSD. K-HP: no conflicts to disclose. JV: speaking and/or consulting fees from Abbott, AbbVie, Bristol-Myers, Squibb, Gilead, Medtronic, Merck/MSD and Roche. GD: speaking and/or consulting fees from Abbvie, Gilead. AG: advisor and steering committee member for AbbVie, Advanz, Albireo, Alexion, Astra Zeneca, Bayer, BMS, CSL Behring, Eisai, Gilead, Heel, Intercept, Ipsen, Merz, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis and as speaker for AbbVie, Advanz, Alexion, BMS, Burgerstein, CSL Behring, Falk, Gilead, Intercept, Merz, MSD, Novartis, NovoNordisk, Roche; research support from Intercept and Falk (NAFLD CSG), Novartis. FPR: honoraria for lectures, consulting activities and travel support from the Falk Foundation, AbbVie, Gilead, Ipsen, Astra Zeneca, Roche and Novartis. TB: speaking and/or consulting fees or travel support from Abbvie, Gilead, SOBI, CSL Behring, Merck, Gore, Advanz. JMS: consultant: Akero, Alentis Therapeutics, Astra Zeneca, Apollo Endosurgery, 89Bio, Boehringer Ingelheim, GSK, Ipsen, Inventiva Pharma, Madrigal, MSD, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Siemens Healthineers. Research Funding: Boehringer Ingelheim, Siemens Healthcare GmbH. Stock Options: AGED diagnostics, Hepta Bio. Speaker Honorarium: Gilead Sciences, Advanz, Echosens, MedPublico GmbH. ED: speaking fees: Abbvie, Gilead. TG: advisory board for GoLiver Therapeutics. CM: speaking and/or consulting fees from Abbvie, Gilead, MSD, Intercept. Research support: Abbvie, Gilead, MSD, Intercept. JT: speaking and/or consulting fees from Abbvie, Gilead, Viiv. TD: Speaking and/or consulting fees: Abbvie, BMS, Gilead, MSD, Roche. JF: no conflicts to disclose. TB: Speaking and/or consulting fees: AbbVie, Alexion, Bayer, Boehringer Ingelheim, BMS, Gilead, GSK, Intercept, Janssen, MSD/Merck, Merz, Novartis, Sequana Medical and Roche. Research support: AbbVie, Roche, BMS, Gilead, Novartis, Merck/MSD, Intercept, Janssen, Novartis, Sequana Medical, and Pfizer. AEK: speaking and/or consulting fees: Abbvie, Advanz, Alentis, AlphaSigma, AOP Orphan, AstraZenca, Avior, Bayer, BMS, CMS, CymaBay, Eisai, Escient, Falk, Gilead, GSK, Guidepoint, Intercept, Ipsen, Lilly, Medscape, Mirum, MSD, Myr, Novartis, Roche, Takeda, Viofor, Zambon. Research support: Intercept, Gilead. BM: speaking and/or consulting fees: Merck/MSD, AbbVie, Intercept, Astra, Bayer, BMS, Gilead. Research support: Gilead. SZ: consultancy and/or speaker's bureau: Abbvie, BioMarin, Boehringer Ingelheim, Gilead, GSK, Ipsen, Madrigal, MSD/Merck, NovoNordisk, and SoBi. CS: speaking and/or consulting fees: AbbVie, Gilead, Merck/MSD. Research support: AbbVie, Gilead.